159 related articles for article (PubMed ID: 9216642)
1. Optimal duration of whole body hyperthermia when combined with cis-diaminne-1,1-cychlobutane dicarboxylate platinum (II) (carboplatin).
Kaneko T; Sakaguchi Y; Makino M; Matsuda H; Strebel FR; Jenkins GN; Bull JM
Anticancer Res; 1997; 17(3C):1897-901. PubMed ID: 9216642
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of long duration-low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats.
Sakaguchi Y; Makino M; Kaneko T; Stephens LC; Strebel FR; Danhauser LL; Jenkins GN; Bull JM
Cancer Res; 1994 Apr; 54(8):2223-7. PubMed ID: 8174130
[TBL] [Abstract][Full Text] [Related]
3. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
[TBL] [Abstract][Full Text] [Related]
4. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats.
Ohno S; Siddik ZH; Baba H; Stephens LC; Strebel FR; Wondergem J; Khokhar AR; Bull JM
Cancer Res; 1991 Jun; 51(11):2994-3000. PubMed ID: 2032236
[TBL] [Abstract][Full Text] [Related]
5. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling.
Baba H; Siddik ZH; Strebel FR; Jenkins GN; Bull JM
Cancer Res; 1989 Dec; 49(24 Pt 1):7041-4. PubMed ID: 2582445
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
Baba H; Stephens LC; Strebel FR; Siddik ZH; Newman RA; Ohno S; Bull JM
Cancer Res; 1991 Jul; 51(13):3568-77. PubMed ID: 1905199
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma.
Wiedemann GJ; d'Oleire F; Knop E; Eleftheriadis S; Bucsky P; Feddersen S; Klouche M; Geisler J; Mentzel M; Schmucker P
Cancer Res; 1994 Oct; 54(20):5346-50. PubMed ID: 7923163
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats.
Sakaguchi Y; Stephens LC; Makino M; Kaneko T; Strebel FR; Danhauser LL; Jenkins GN; Bull JM
Cancer Res; 1995 Nov; 55(22):5459-64. PubMed ID: 7585616
[TBL] [Abstract][Full Text] [Related]
9. Optimal duration of whole body hyperthermia when combined with cis-diamminedichloroplatinum(II).
Makino M; Ohno S; Sakaguchi Y; Kaneko T; Strebel F; Jenkins G; Bull J
Int J Oncol; 1997 Feb; 10(2):329-32. PubMed ID: 21533380
[TBL] [Abstract][Full Text] [Related]
10. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury.
Wondergem J; Bulger RE; Strebel FR; Newman RA; Travis EL; Stephens LC; Bull JM
Cancer Res; 1988 Jan; 48(2):440-6. PubMed ID: 3335012
[TBL] [Abstract][Full Text] [Related]
11. Single and fractionated whole body hyperthermia in murine fibrosarcoma.
Lahiri T; Roy D; Chowdhury S
Arch Geschwulstforsch; 1988; 58(2):81-8. PubMed ID: 3377651
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer.
Richel O; Zum Vörde Sive Vörding PJ; Rietbroek R; Van der Velden J; Van Dijk JD; Schilthuis MS; Westermann AM
Gynecol Oncol; 2004 Dec; 95(3):680-5. PubMed ID: 15581981
[TBL] [Abstract][Full Text] [Related]
13. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of NG-monomethyl-L-arginine against hypotension inducted by combined tumour necrosis factor-alpha and whole body hyperthermia in rats.
Makino M; Lodato RF; Stephens LC; Strebel FR; Jenkins G; Ohno S; Sakaguchi Y; Kostergaard J; Tomasovic SP; Bull JM
Int J Hyperthermia; 1996; 12(5):617-34. PubMed ID: 8886889
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.
Robins HI; Cohen JD; Schmitt CL; Tutsch KD; Feierabend C; Arzoomanian RZ; Alberti D; d'Oleire F; Longo W; Heiss C
J Clin Oncol; 1993 Sep; 11(9):1787-94. PubMed ID: 8355046
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of carboplatin combined with hyperthermia on Ehrlich-ascites tumor in vivo.
Mizuuchi H; Yoshiga K; Sakurai K; Tsumura M; Takada K
Anticancer Res; 1996; 16(1):381-7. PubMed ID: 8615640
[TBL] [Abstract][Full Text] [Related]
17. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
18. Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.
Wondergem J; Stephens LC; Strebel FR; Baba H; Ohno S; Siddik ZH; Newman RA; Bull JM
Cancer Res; 1991 Jul; 51(13):3559-67. PubMed ID: 2054792
[TBL] [Abstract][Full Text] [Related]
19. Effect of altered duration of 41.5 degrees C whole body hyperthermia in combination with cis-diamminedichloroplatinum (II) on tumor and normal tissue apoptosis and tumor response in rats.
Toyota N; Strebel FR; Stephens LC; Rowe W; Matsuda H; Oshiro T; Jenkins GN; Bull JM
Oncol Rep; 1998; 5(5):1231-6. PubMed ID: 9683841
[TBL] [Abstract][Full Text] [Related]
20. Optimal scheduling increases therapeutic gain of adriamycin combined with hyperthermia.
Baba H; Maehara Y; Takeuchi H; Inutsuka S; Sugimachi K
Anticancer Res; 1993; 13(3):651-4. PubMed ID: 8317893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
